Skip to main content
. 2023 Oct 30;11(11):1664. doi: 10.3390/vaccines11111664

Figure 1.

Figure 1

Proportions of those failing to achieve robust/above-average responses at T3 and T5, using 2 endpoints VE90% (vaccine efficacy of 90% in preventing symptomatic infections) and OCOnAbs (optimal cut-off for binding Ab calculated for a nAb titer ≥ 1:40) according to the CD4 count (A) and to the CD4/CD8 ratio (B) at the time of first vaccination.